ReviewIndian journal of pediatrics2017
Diagnosis and Management of Rhabdomyosarcoma in Children and Adolescents: ICMR Consensus Document.
Review in Indian journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Predictors of survival among children and adolescents with rhabdomyosarcoma treated in a single resource-limited centre -Uganda.BMC cancer · 2025Article
- Diagnosis and treatment of cardiac tumors.Medical oncology (Northwood, London, England) · 2025Review
- Article
- Suboptimal outcomes of group III paediatric genitourinary rhabdomyosarcoma-experience from treatment with a multimodal protocol in low- and middle-income setting.Ecancermedicalscience · 2025Article
- Non-inferior efficacy of non-surgical treatment to surgical treatment in patients with nonmetastatic head and neck rhabdomyosarcoma: a SEER-based study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Long-Term Outcome and Quality of Life in Patients Treated for Head and Neck Sarcoma during Pediatric Age: Considerations from a Series of 4 Cases.Reports (MDPI) · 2023Article
- Multimodality imaging assessment of primary pericardial rhabdomyosarcoma: a case report.Frontiers in cardiovascular medicine · 2023Article
- About a Large Botryoid Rhabdomyosarcoma in a Little Girl: Management Difficulties and Literature Review.Case reports in obstetrics and gynecology · 2023Article
- Outcome and prognostic variables in childhood rhabdomyosarcoma (RMS) with emphasis on impact of FOXO1 fusions in non-metastatic RMS: experience from a tertiary cancer centre in India.Ecancermedicalscience · 2023Article
- Infant prostatic Rhabdomyosarcoma: A diagnostic and therapeutic challenge.Urology case reports · 2022Article
- Circular RNA ZNF609/CKAP5 mRNA interaction regulates microtubule dynamics and tumorigenicity.Molecular cell · 2022Article
- Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma.Cancer medicine · 2021Article
- Cardiac Tumors:JACC. CardioOncology · 2020Review
- CT-Based Radiomics to Differentiate Pelvic Rhabdomyosarcoma From Yolk Sac Tumors in Children.Frontiers in oncology · 2020Article
- CD56-chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma: A 3.5-year follow-up case report.Medicine · 2019Article
- Review
- Oropharyngeal Rhabdomyosarcoma with cranial nerve paralysis in a limited resource setting: a case report and review of literature.The Pan African medical journal · 2019Review
- A Mass Filling the Right Atrium: Primary Cardiac Rhabdomyosarcoma.Internal medicine (Tokyo, Japan) · 2018Article
- Pediatric soft tissue sarcoma of the limbs: clinical outcome of 97 patients.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2018Article
- Prognostic factors for postoperative survival among patients with rhabdomyosarcoma of the limbs.Cancer management and research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma (RMS) is a highly malignant tumor which is thought to originate from the pluripotent mesenchyme. It is the most common soft-tissue sarcoma of childhood. This review article summarizes the recent and older published literature and gives an overview of management of RMS in children. RMS can arise in a wide variety of primary sites, some of which are associated with specific patterns of local invasion, regional lymph nodal spread, therapeutic response and long term outcome, hence requiring physicians to be familiar with site-specific staging and treatment details. Most common primary sites include the head and neck region, genitourinary tract, and extremities. Prognosis for children and adolescents with RMS has recently improved substantially, especially for patients with local or locally extensive disease because of the development of multi-modal therapy incorporating surgery, dose-intensive combination chemotherapy, and radiation therapy. Despite aggressive approaches the outcome for patients who present with metastatic disease remains unsatisfactory. Clinical trials are ongoing to reduce toxicity and improve outcomes of such patients; newer agents in combination are being investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.